Denosumab is a lab-made antibody that helps slow down bone breakdown. It belongs to a class of medicines called RANKL inhibitors, used to treat osteoporosis and to prevent bone-related complications in certain cancers. It is a prescription-only injectable medicine, marketed under two different brand names for two different dosing schedules and uses.

• Therapeutic Class: Bone-modifying agent / anti-resorptive therapy.

• Pharmacological Class: RANKL (receptor activator of nuclear factor kappa-B ligand) inhibitor, monoclonal antibody.

• Drug Family: Human IgG2 monoclonal antibodies.

• ATC Classification: M05BX04 (Denosumab).

Approved: Postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and cancer treatment-induced bone loss (lower-dose formulation, brand Prolia); prevention of skeletal-related events in patients with bone metastases from solid tumours or multiple myeloma, giant cell tumour of bone, and hypercalcemia of malignancy (higher-dose formulation, brand Xgeva).

Commonly used for: Postmenopausal women and men at high risk of fracture, and cancer patients at risk of bone complications from metastatic disease.

Off-label use (only under medical guidance): Occasionally used for other bone-density conditions under specialist review.

● Injection (Prolia, subcutaneous): 60 mg/mL single-use prefilled syringe.

● Injection (Xgeva, subcutaneous): 120 mg/1.7 mL single-use vial.

Bone is constantly being broken down and rebuilt by cells called osteoclasts and osteoblasts. A protein called RANKL drives the activity and survival of osteoclasts, the cells that break down bone. Denosumab attaches to RANKL and blocks it from activating osteoclasts, slowing bone breakdown and helping preserve bone strength.

• Standard dose (osteoporosis, Prolia): 60 mg subcutaneously once every 6 months, with mandatory daily calcium (1,000 mg) and vitamin D (at least 400 IU) supplementation.

• Standard dose (bone metastases, Xgeva): 120 mg subcutaneously every 4 weeks.

• Condition-wise dose: For giant cell tumour of bone, 120 mg monthly after three additional loading doses in the first month (days 1, 8, and 15).

• Route: Subcutaneous injection, given in the upper arm, upper thigh, or abdomen.

• Missed dose: For osteoporosis dosing, administer as soon as possible, then schedule the next injection 6 months from that date.

• Overdose: Not well established beyond recommended doses; monitored by the treating clinician if it occurs.

• Common: Back pain, joint/muscle pain, high cholesterol, and bladder infections (osteoporosis dosing); fatigue, low phosphate and calcium levels, and nausea (oncology dosing).

• Serious: Severe hypocalcemia, osteonecrosis of the jaw, atypical femur fractures with long-term use, and serious infections.

• Emergency symptoms: Muscle spasms, numbness/tingling around the mouth or in fingers/toes, new hip/thigh/groin pain, jaw pain or exposed bone in the mouth, or signs of a severe allergic reaction.

• Recovery advice: Ensuring adequate calcium and vitamin D intake before and during treatment substantially reduces the risk of low blood calcium; a dental check-up before starting is recommended to lower osteonecrosis risk.

• Pregnancy: Not recommended; may cause fetal harm.

• Breastfeeding: Not recommended during treatment.

• Liver disease: No specific dose adjustment established.

• Kidney disease: Used with caution in severe impairment or dialysis patients, given higher risk of hypocalcemia.

• Elderly: Commonly used in this age group; monitored for calcium levels and infection risk.

• Children: Xgeva approved for skeletally mature adolescents with giant cell tumour of bone; not approved for osteoporosis in children.

● Calcium and vitamin D supplements: not an interaction to avoid — required alongside denosumab to reduce hypocalcemia risk.

● Other bone-active medicines (bisphosphonates): not typically combined.

● Immunosuppressive medicines: may increase the risk of infection or osteonecrosis of the jaw when combined.

● Corticosteroids: combined long-term use may increase fracture and infection risks that need closer monitoring.

● Blood calcium levels, especially before each dose and in patients with kidney impairment.

● Dental examination before starting, particularly for cancer patients on the higher-dose schedule.

● Bone density scans periodically (osteoporosis use).

● Kidney function tests periodically.

Alendronate, Zoledronic acid, Risedronate (bisphosphonates); Teriparatide, Romosozumab (bone-building agents, for osteoporosis).

Generally used as a standalone bone-targeted therapy; not combined with bisphosphonates. In cancer settings, used alongside the primary cancer treatment rather than replacing it.

● Osteoporosis Medicines

● Bone Metastasis / Skeletal-Related Event Prevention

● RANKL Inhibitors

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125320s094lbl.pdf

2. https://www.ncbi.nlm.nih.gov/books/NBK535388/

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.